This is an ongoing observational registry record with no results posted; it describes a planned blood collection study to characterize tarlatamab pharmacology in real-world SCLC treatment.
Reported
Planned sample size25
Primary outcome measureNumber of blood samples collected to better…
Blood collection timepointsDays 1, 8, and 15 of tarlatamab treatment,…